569 results about "Protein antigen" patented technology

Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP.

Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.

The invention relates to an SARS-CoV-2 neutralizing antibody detection kit. The SARS-CoV-2 neutralizing antibody detection kit comprises a solid phase carrier, an S protein antigen of SARS-CoV-2 and acompetitive substance. The competitive substance is marked with a signal substance and can be specifically combined with the new coronavirus S protein antigen. Whether a tested person is infected bythe new coronavirus or not and whether infection risks exist or not are judged by detecting a neutralizing antibody through an immunodiagnosis technology, and the method is reliable in theory, practical and feasible and can be completed only in a secondary biosafety laboratory.

Streptococcus proteins and polynucleotides encoding them are disclosed. Said proteins are antigenic and therefore useful vaccine components for the prophylaxis or therapy of streptococcus infection in animals. Also disclosed are recombinant methods of producing the protein antigens as well as diagnostic assays for detecting streptococcus bacterial infection.

Provided is a detection apparatus of Raman scattering and light scattering, and more particularly, a simultaneous detection apparatus of Raman scattering and dynamic light scattering and a detection method using the same. The simultaneous detection apparatus of Raman scattering and light scattering includes: a detection unit for applying incident light to a sample, and detecting Raman scattering in 90° or 180° geometry and light scattering in 90° or 180° geometry in order to simultaneously collect Raman scattering and light scattering; and a computer connected to the detection unit to obtain at least one of the size and distribution of particles from the detected light scattering, and to obtain information of the molecular structure from the detected Raman scattering. This apparatus may simultaneously observe the size of nano-sized or larger material and molecular information thereof, and phenomena accompanying changes in molecular environment according to material variation and changes of the material in size and distribution, and thus is very useful for studying nano materials and protein antigens and antibodies.

A small number of defined antigens can provide broad protection against meningococcal infection, and the invention provides a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or three of hypervirulent lineages A4, ET 5 and lineage 3 of N. meningitidis serogroup B. Rather than consisting of a single antigen, the composition comprises a mixture of 10 or fewer purified antigens, and should not include complex or undefined mixtures of antigens such as outer membrane vesicles. Five protein antigens are used in particular: (1) a ‘NadA’ protein; (2) a ‘741’ protein; (3) a ‘936’ protein; (4) a ‘953’ protein; and (5) a ‘287’ protein.

The invention provides a pneumococcal polysaccharide and protein conjugated vaccine and a preparation method thereof. The pneumococcus polysaccharide protein conjugated vaccine comprises one or more streptococcus pneumoniae capsular polysaccharide and protein coupled immune conjugates, and at least one of the immune conjugates is formed by coupling a single streptococcus pneumoniae capsular polysaccharide with two or more proteins. Compared with the existing pneumococcal conjugated vaccine, the pneumococcal polysaccharide and protein conjugated vaccine has stronger immunogenicity, and can cause immune response in a wider crowd; meanwhile, the two carrier proteins are covalently coupled through the polysaccharide, the protective protein antigen epitope induces higher immune response compared with the mixed injection of the two proteins, and through mutual synergy, the immunogenicity of the carrier protein is further improved and the immune response of the body to the polysaccharide is improved; the preparation method is simple, and meets the requirement of large-scale industrial production.

The invention discloses a kit of chemiluminescent immunological analysis measurement of a Treponema pallidum antibody, and preparation method thereof, which belongs to the technical field of immunological analysis medical diagnosis. The kit comprises (1) a carrier coated with a treponema pallidum specific recombination protein antigen; (2) treponema pallidum antibody negative and positive reference substances; (3) an enzyme labeled treponema pallidum specific recombination protein antigen; and (4) an enzyme acted chemiluminescent primer. Furthermore, the preparation method of the kit based on the invention comprises the following steps of (1) preparing TP antibody negative and positive reference substances; (2) labeling the TP specific recombination protein antigen with an enzyme; (3) coating with the carrier; (4) sub-packaging; and (5) assembling. The kit of the detection of the Treponema pallidum antibody has the advantages of easy and simple operation, easy popularization, high sensitivity, strong specificity, good repeatability, safety, non toxicity, and no pollution.

The present application is generally directed to novel pneumococcal polypeptide antigens and nucleic acids encoding such antigens, and immunogenic compositions comprising such antigens for treating and preventing pneumococcal infection. The present invention further provides method of using the antigens to elicits an immune response (e.g., IL-17A response, a T cell-mediated and / or B-cell-mediated immune responses). The present invention also provides methods of prophylaxis and / or treatment of pneumococcal-mediated diseases, such as sepsis, comprising administering an immunogenic composition including one or more of a combination of pneumococcal antigens or functional fragments thereof as disclosed herein. In some embodiments, one or more pneumococcal antigens can be present in a polysaccharide conjugate. The compositions induce an anti-pneumoccocus immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and / or therapeutically to induce a thereapeutic immune response to an infected individual.

A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.

The invention relates to nanoliposome human papillomavirus (HPV) resistant and gynecological inflammation pathogen resistant specific complex IgY and a combined preparation for the same. Laying poultry is preferred to respectively prepare laying poultry for immunity of tumor somatic cells, viral protein complex antigens, gene recombination protein antigens and bacterial virus complex antigens; and human papillomavirus resistant special IgY and gynecological inflammation pathogen resistant specific IgY undergo affinity chromatography and purification and are converted into nanoliposomes, and then the nanoliposome special complex IgY is prepared. The nanoliposome human papillomavirus (HPV) resistant and gynecological inflammation pathogen resistant specific complex IgY and the combined preparation for the same have the advantages that: the nanoliposome technology is applied to increase the infiltration capacity and the prolongation effect and improve the curative effect. The nanoliposome human papillomavirus (HPV) resistant and gynecological inflammation pathogen resistant specific complex IgY and the combined preparation for the same can be prepared into various vaginal spraying agents, other spraying agents, lotion, gel, capsules, suppository, vaginal membranes, tablets, effervescent tablets, ointment, cream and so on. The nanoliposome complex IgY can infiltrate into a vagina mucosa to effectively remove HPV viruses and gynecological inflammation pathogens which are absorbed on the vaginal surface layer and in the vagina mucosa, is absorbed through the vagina mucosa and enters into the body to give play to the functions of prevention and treatment, and also can effectively prevent recrudescence.

Conjugated capsular saccharides from meningococcal serogroups C, W135 and Y are safe and immunogenic in humans when combined in a single dose. This effect is retained when a conjugated capsular saccharide from serogroup A is added. These conjugated antigens can be stably combined in a single aqueous dose without the need for lyophilisation. Broad protection against serogroup B infection can be achieved by using a small number of defined polypeptide antigens. These polypeptide antigens can be combined with the saccharide antigens without loss of protective efficacy for any of the five serogroups. Efficacy if retained even if a Hib conjugate is added. The efficacy of a serogroup W135 conjugate is enhanced by addition of protein antigens derived from a serogroup B strain. Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W135.

An isolated protein construct comprising a polyepitope derived from multiple human cytomegalovirus protein antigen epitopes conjugated to an extracellular domain of glycoprotein B, which isolated protein is capable of eliciting a cytotoxic T-lymphocyte immune response as well as a neutralizing antibody response to human cytomegalovirus. Also provided are pharmaceutical compositions comprising the isolated protein or an adenoviral expression construct for delivery and expression of a nucleic acid encoding the isolated protein for prophylactic and / or therapeutic treatment of human cytomegalovirus infection, particularly in humans.